产品名称
AD 198, ≥98% (HPLC), solid
SMILES string
CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NCc3ccccc3)[C@H](O)[C@H](C)O2)c4c(O)c5C(=O)c6c(OC)cccc6C(=O)c5c(O)c4C1
assay
≥98% (HPLC)
form
solid
color
red
solubility
DMSO: >10 mg/mL
H2O: insoluble
storage temp.
2-8°C
Biochem/physiol Actions
AD 198 is a PKC-delta activator.
AD 198 is a PKC-delta activator. Phospholipid scramblase 3 (PLS3) is an enzyme that plays a critical role in mitochondrial morphology, functions, and apoptotic response. During apoptosis, activated protein kinase C-delta (PKC-delta) translocates to mitochondria and phosphorylates PLS3. Used to show that PLS3 is a critical downstream effector of PKC-delta in AD 198-induced apoptosis.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
A Harstrick et al.
Anti-cancer drugs, 6(5), 681-685 (1995-10-01)
The new lipophilic anthracycline N-benzyl-adriamycin-14-valerate (AD198) was evaluated for its activity in comparison to doxorubicin in P-glycoprotein (Pgp)-positive and -negative cell lines. AD198 and doxorubicin showed comparable antitumor activity in the Pgp-negative breast cancer cell line MCF-7 and the Pgp-negative
L Lothstein et al.
Cancer research, 52(12), 3409-3417 (1992-06-15)
N-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s)
L Lothstein et al.
Oncology research, 5(6-7), 229-234 (1993-01-01)
N-Benzyladriamycin-14-valerate (AD 198)-resistant murine J774.2 macrophage-like cells (A300) exhibited a novel mechanism of resistance in which P-glycoprotein was overexpressed without decreased AD 198 accumulation. Cross-resistance to Adriamycin (ADR), N-benzyladriamycin, and Adriamycin-14-valerate was due, at least in part, to reduced accumulation
J Brent Roaten et al.
Molecular cancer therapeutics, 1(7), 483-492 (2002-12-14)
Anthracycline antibiotics like doxorubicin (DOX) are known to exert their antitumor effects primarily via DNA intercalation and topoisomerase II inhibition. By contrast, the noncross-resistant cytoplasmically localizing DOX analogue, N-benzyladriamycin-14-valerate (AD 198), only weakly binds DNA and does not inhibit topoisomerase
R Ganapathi et al.
British journal of cancer, 60(6), 819-826 (1989-12-01)
N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cellular pharmacokinetics and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持